The history and future of probenecid

Cardiovascular Toxicology

Volumn 12, Issue 1, 2012, Pages 1-9

  Robbins, Nathan ^a   Koch, Sheryl E ^a   Tranter, Michael ^b   Rubinstein, Jack ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

History; Probenecid; Review

Indexed keywords

ADINAZOLAM; ALLOPURINOL; AMPICILLIN; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; BENZODIAZEPINE DERIVATIVE; CARINAMIDE; CARPROFEN; CEFAZOLIN; CIDOFOVIR; CIPROFLOXACIN; COLCHICINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EMTRICITABINE; FIBRIC ACID DERIVATIVE; FUROSEMIDE; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROCHLOROTHIAZIDE; INDOMETACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OSELTAMIVIR; PENICILLIN G; POLYCYCLIC AROMATIC HYDROCARBON; PROBENECID; SULFONAMIDE; VANILLOID RECEPTOR 2; XANTHINE OXIDASE INHIBITOR;

ABDOMINAL PAIN; BLOOD TOXICITY; BRAIN PROTECTION; CRYSTALLURIA; DEPRESSION; DIURETIC ACTIVITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG COST; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPNEA; GASTROINTESTINAL SYMPTOM; GOUT; HUMAN; HYPERURICEMIA; KIDNEY COLIC; LIVER NECROSIS; LIVER TOXICITY; MYALGIA; NAUSEA AND VOMITING; NEPHROLITHIASIS; NEPHROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SEROTONIN SYNDROME; SINGLE DRUG DOSE; SKIN IRRITATION; TREATMENT RESPONSE; URINARY EXCRETION; VASOMOTOR DISORDER;

ANIMALS; ANTI-BACTERIAL AGENTS; DEPRESSION; FURA-2; GOUT; HUMANS; PROBENECID; TRPV CATION CHANNELS; URICOSURIC AGENTS;

EID: 84858792470     PISSN: 15307905     EISSN: 15590259     Source Type: Journal    
DOI: 10.1007/s12012-011-9145-8     Document Type: Review

References (83)

1. Anjak, A., Haar, L., Min, J., Durga, S., Ren, X., Tranter, M., et al. (2010). Transient receptor potential vanilloid 2 (TRPV2) stimulation is cardioprotective. Journal of Investigative Medicine, 58, 4632.
2. Ashcroft, G. W., Dow, R. C., & Moir, A. T. B. (1968). The active transport of 5-Hydroxyindol-3-ylacetic Acid and 3-Methoxy-4- hydroxyphenyl acetic acid from a recirculatory perfusion system of the cerebral ventricles of the unanaesthesized dog. Journal of Physiology, 199, 397-425.
3. Bakos, E., Evers, R., Sinkó, E., Váradi, A., Borst, P., & Sarkadi, B. (2000). Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Molecular Pharmacology, 57, 760-768. (Pubitemid 30183717)
4. Bang, S., Kim, K. Y., Too, S., Lee, S. H., & Hwang, S. W. (2007). Transient receptor potential Ve expressed in sensory neurons is activated by Probenecid. Neuroscience Letters, 435, 120-125. (Pubitemid 47410367)
5. Barza, M., Brusch, J., Bergeron, M. G., & Weinstein, L. (1974). Penetration of antibiotics into fibrin loci in vivo. 3. Intermittent vs. continuous infusion and the effect of probenecid. Journal Infectious Disease, 129(1), 73-78.
6. Beyer, K. H., Flippin, H. F., Verwey, W. F., & Woodward, R. (1944). Effect of para-aminohippuric acid on plasma concentration of penicillin in man. The Journal of American Medical Association, 126, 1007.
7. Beyer, K. H., Miller, K. A., Russo, H. F., Patch, E. A., & Verwey, W. F. (1947). The inhibitory effect of Carinamide on renal elimination of penicillin. American Journal of Physiologic, 149, 355-368.
8. Beyer, R. H., Wiebelhaus, V. D., Russe, H. F., Peck, H. M., & McKinney, S. E. (1950). Benemid: An anticatabolite; its pharmacological properties. Federation Proceedings, 9, 258.
9. Beyer, K. H., Russo, H. F., Tillson, E. K., Miller, A. K., Verwey, W. F., & Gass, S. R. (1951). 'Benemid', p-(di-n-propylsulfamyl)- benzoic acid; its renal affinity and its elimination. American Journal of Physiologic, 166(3), 625-640.
10. Bishop, C., & Pfaff, W. (1955). Immediate uricosuric effect of probenecid in normal humans. Proceedings of the Society for Experimental Biology and Medicine, 88(3), 346-348.
11. Boger, W. P., Beatty, J. O., Pitts, F., & Flippin, H. F. (1950). The influence of a new benzoic acid derivative on the metabolism of para-aminosalicylic acid (PAS) and penicillin. Annals of Internal Medicine, 33(1), 18-31.
12. Boger, W. P., Pitts, F. W., & Gallagher, M. E. (1950). Benemid and carinamide: Comparison of effect on Para-amino-salicylic acid (PAS) plasma concentrations. Journal of Laboratory and Clinical Medicine, 36, 276-282.
13. Boger, W. P., & Pitts, F. W. (1950). Influence of p-(di-n-propylsulfamyl)- benzoic acid, "benemid", on para-aminosalicylic acid (PAS) plasma concentrations. American Review of Tuberculosis, 61(6), 862-867.
14. Boger, W. P., & Strickland, S. C. (1955). Probenecid (Benemid): Its uses and side effects in 2502 Patients. American Medical Association Archives of Internal Medicine, 95, 83-92.
15. Bronfenbrenner, J., & Favour, C. B. (1945). Increasing and prolonging blood penicillin concentrations following intramuscular administration. Science, 101, 673-674.
16. Bronsky, D., Dubin, A., & Kusher, D. S. (1955). Diuretic action of benemid: Its effects upon the urinary excretion of sodium, chloride, potassium, and water in edematous subjects. American Journal of Medicine, 18, 259-266.
17. Butler, D. (2005). Wartime tactics doubles power of scarce bird-flu drug. Nature, 438, 6.
18. Caterina, M. J., Schumacher, M. A., Tominaga, M., Rosen, T. A., Levine, J. D., & Julius, D. (1997). The capsaicin receptor: A heat-activated ion channel in the pain pathway. Nature, 389, 816-824. (Pubitemid 27462969)
19. Caterina, M. J., Rosen, T. A., Tominaga, M., Brake, A. J., & Julius, D. (1999). A capsaicin-receptor homologue with a high threshold for noxious heat. Nature, 398, 436-441. (Pubitemid 29180377)
20. Chung, Y., Lu, C. Y., Graham, G. G., Mant, A., & Day, R. O. (2008). Utilization of allopurinol in the Australian community. Internal Medicine of Journal, 38(6), 388-395. (Pubitemid 351871974)
21. Cunningham, R. F., Israili, Z. H., & Dayton, P. G. (1981). Clinical pharmacokinetics of probenecid. Clinical Pharmacokinetics, 6, 135-151. (Pubitemid 12164164)
22. Day, R. O., Miners, J. O., Birkett, D. J., Whitehead, A., Naidoo, D., Hayes, J., et al. (1988). Allopurinol dosage selection: Relationships between dose and plasma oxipurinol and urate concentrations and urinary urate excretion. British Journal of Clinical Pharmacology, 26(4), 423-428.
23. Despopoulos, A., & Weissbach, H. (1957). Renal metabolism of 5-hydroxyindolacetic acid. American Journal of Physiology, 189, 548-550.
24. Di Virgilio, F., Steinberg, T. H., Swanson, J. A., & Silverstein, S. C. (1988). Fura-2 secretion and sequestration in macrophages. A blocker of organic anion transport reveals that these processes occur via a membrane transport system for organic anions. Journal of Immunology, 140(3), 915-920. (Pubitemid 18067283)
25. Erttmann, R. R. (1978). Kinetics and inotropic action of probenecid in guinea-pig heart in vitro. Cellular and Molecular Life Sciences, 34(12), 1620-1622.
26. Forbes, M., & Becker, B. (1960). The transport of organic anions by the rabbit eye. II. In vivo transport of iodopyracet (Diodrast). American Journal of Ophthalmology, 50, 867-875.
27. Gordon, E. K., Markey, S. P., Sherman, R. L., & Kopin, I. J. (1976). Conjugated 3, 4 dihydroxyphenyl acetic acid (DOPAC) in human and monkey cerebrospinal fluid and rat brain and the effects of Probenecid. Life Sciences, 18, 1285-1292.
28. Greene, T. A., Alarcon, S., Thomas, A., Berdougo, E., Doranz, B. J., Breslin, P. A. S., & Rucker, J. B. (2011) Probenecid inhibits the human bitter taste receptor TAS2R16 and suppresses bitter perception of salicin. PLOS One, 6(5), e20123.
29. Grynkiewicz, G., Poenie, M., & Tsien, R. Y. (1985). A new generation of Ca2? indicators with greatly improved fluorescence properties. Journal of Biological Chemistry, 260(6), 3440-3450. (Pubitemid 15114340)
30. Guldberg, H. C., Ashcroft, G. W., & Crawford, T. B. B. (1966). Concentration of 5-hydroxyindolyacetic acid and homovanillic acid in the cerebrospinal fluid of the dog before and during treatment with Probenecid. Life Sciences, 5, 1571-1575.
31. Gutman, A. B. (1950). Uric acid metabolism in gout. American Journal of Medicine, 9(6), 799-817.
32. Gutman, A. B., & Yu, T. F. (1951). Benemid (p-di-n-propylsulfamyl)- benzoic acid) as uricosuric agent in chronic gouty arthritis. Transactions of the Association of American Physicians, 64, 279-288.
33. Haar, L., Rubinstein, J., & Tranter, M., et al. (2010) Myocardial TRPV activation associated with high fat diet and cardioprotection. FASEB Journal, 24, 57314.
34. Hilaire, M. L., & Wozniak, J. R. (2010). Gout: Overview and newer therapeutic developments. Formulary, 45, 84-90.
35. Hill, G., Cihlar, T., Oo, C., Ho, E. S., Prior, K., Wiltshire, H., et al. (2002). The Anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactins via renal secretion-correlation of in vivo and in vitro studies. Drug Metabolism Disposition, 30, 13-19. (Pubitemid 34016935)
36. Hilton, A. L. (1959). Treatment of gonorrhoea with P.A.M., & probenecid. The British Journal of Venereal Diseases, 35, 249-251.
37. Hilton, A. L. (1971). PAM plus probenecid and procaine penicillin plus probenecid in gonorrhoea. The British Journal of Venereal Diseases, 47(2), 107-110.
38. Hu, H. Z., Gu, Q., Wang, C., Colton, C. K., Tang, J., Kinoshita- Kawada, M., et al. (2004). 2-aminoethoxydiphenyl borate is a common activator of TRPV1, TRPV2, and TRPV3. Journal of Biological Chemistry, 279(34), 35741-35748. (Pubitemid 39100579)
39. Insel, P. A. (1996). Analgesic-antipyretic and anti-inflammatory agents and drugs employed in the treatment of gout. In J. G. Hardman, L. E. Limbird, P. B. Molinoff, R. W. Ruddon, & A. Goodman Gilman (Eds.), Gilman's Goodman the pharmacological basis of therapeutics (9th ed., pp. 617-657). USA: McGraw-Hill.
40. Israili, Z. H., Percel, J. M., Cunningham, R. F., Dayton, P. G., Yü, T. F., Gutman, A. B., et al. (1972). Metabolites of probenecid. Chemical, physical, and pharmacological studies. Journal of Medicinal Chemistry, 15(7), 709-713.
41. Juvin, V., Penna, A., Chemin, J., Lin, Y. L., & Rassendren, F. A. (2007). Pharmacological characterization and molecular determinants of the activation of transient receptor potential V2 channel orthologs by 2-aminoethoxydiphenyl borate. Molecular Pharmacology, 72(5), 1258-1268. (Pubitemid 350012599)
42. Kahn, A. M., & Weinman, E. J. (1985). Urate transport in the proximal tubule: In vivo and in vesicle studies. American Journal of Physiology, 249, F789-F798. (Pubitemid 16171210)
43. Keenan, R., O'brien, W., Lee, K., Crittenden, D., Fisher, M., Goldfarb, D., et al. (2011). Prevalence of contraindications and prescription of pharmacologic therapies for gout. The American Journal of Medicine, 124(2), 155-163.
44. Kenwright, S., & Levi, A. J. (1973). Impairment of hepatic uptake of rifamycin antibiotics by probenecid, and its therapeutic implications. Lancet, 302(7843), 1401-1405.
45. Korf, J., & van Praag, H. M. (1970). The intravenous probenecid test: A possible aid in evaluation of the serotonin hypothesis on the pathogenesis of depressions. Psychopharmacologia, 18(1), 129-132.
46. Kunert-Keil, C., Bisping, F., Krüger, J., & Brinkmeier, H. (2006). Tissue-specific expression of TRP channel genes in the mouse and its variation in three different mouse strains. BMC Genomics, 7, 159.
47. Kushner, D., Dubin, A., & Bronsky, D. (1954). Effect of Benemid on excretion of water, sodium and chloride in congestive heart failure. Federation Proceedings, 13, 435.
48. Kuzell, W., Schaffarzick, R., Naugler, W., Koets, P., Mankle, E., Brown, B., et al. (1955). Some observations on 520 gouty patients. Journal of Chronic Diseases, 2(6), 645-669.
49. Lake, C. R., Wood, J. H., Ziegler, M. G., Ebert, M. H., & Kopin, I. J. (1978). Probenecid-induced norepinephrine elevations in plasma and CSF. Archives of General Psychiatry, 35, 237-240. (Pubitemid 9206971)
50. Landersdorfer, C. B., Kirkpatrick, C. M., Kinzig, M., Bulitta, J. B., Holzgrabe, U., Jaehde, U., et al. (2010). Competitive inhibition of renal tubular secretion of ciprofloxacin and metabolite by Probenecid. British Journal of Clinical Pharmacology, 69, 167-178.
51. Malgaroli, A., Milani, D., Meldolesi, J., & Pozzan, T. (1987). Fura-2 measurement of cytosolic free Ca2 ? in monolayers and suspensions of various types of animal cells. Journal of Cell Biology, 105(5), 2145-2155. (Pubitemid 18019065)
52. McDonough, P. M., & Button, D. C. (1989). Measurement of cytoplasmic calcium concentration in cell suspensions: Correction for extracellular fura-2 through use of Mn2 + and probenecid. Cell Calcium, 10(3), 171-180. (Pubitemid 19096306)
53. McKinney, S. E., Peck, H. M., Bochey, J. M., Byham, B. B., Schuchardt, G. S., & Beyer, K. H. (1951). Benemid p-(di-n-sulfyaml)- benzoid acid; toxicologic properties. The Journal of Pharmacology and Experimental Therapeutics, 102(3), 208-214.
54. Meads, M., Knight, V. H., & Izlar, H. L., Jr. (1951). The enhancement of serum penicillin in man by benemid. Southern Medical Journal, 44(4), 297-302.
55. Mitsui, M., Abe, A., Tajimi, M., & Karaki, H. (1993). Leakage of the fluorescent Ca2 ? indicator fura-2 in smooth muscle. Japanese Journal of Pharmacology, 61(3), 165-170. (Pubitemid 23123439)
56. Münnich, D., Békési, S., Lakatos, M., & Bardovics, E. (1974). Treatment of typhoid carriers with amoxycillin and in combination with probenecid. Chemotherapy, 20(1), 29-38.
57. Neff, N. H., Tozer, T. N., & Brodie, B. B. (1967). Application of steady-state kinetics to studies of the transfer of 5-hydroxyindolacetic acid and from brain to plasma. The Journal of Pharmacology and Experimental Therapeutics, 158, 214-218.
58. Penna, A., Juvin, V., Chemin, J., Compan, V., Monet, M., & Rassendren, F. A. (2006). PI3-kinase promotes TRPV2 activity independently of channel translocation to the plasma membrane. Cell Calcium, 39(6), 495-507.
59. Perel, J. M., Cunningham, R. F., Fales, H. M., & Dayton, P. G. (1970). Identification and renal excretion of probenecid metabolites in man. Life Sciences Pt. I: Physiology and Pharmacology, 9(23), 1337-1343.
60. Qin, N., Neeper, M. P., Liu, Y., Hutchinson, T. L., Lubin, M. L., & Flores, C. M. (2008). TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons. Journal of Neuroscience, 28(24), 6231-6238.
61. Rammelkamp, C. H., & Bradley, S. E. (1943). Excretion of penicillin in man. Proceedings of Society Experimental Biology and Medicine, 53, 30.
62. Reynolds, E. S., Schlant, R. C., Gonick, H. C., & Dammin, G. J. (1957). Fatal Massive Necrosis of the liver as a manifestation of hypersensitivity to probenecid. New England Journal of Medicine, 256, 592-596.
63. Rider, T. G., & Jordan, K. M. (2010). The modern management of gout. Rheumatology (Oxford), 49(1), 5-14.
64. Roch-Ramel, F., & Guisan, B. (1999). Renal transport of urate in humans. News Physiol Science, 14, 80-84.
65. Rose, R. A., Hatano, N., Ohya, S., Imaizumi, Y., & Giles, W. R. (2007). C-type natriuretic peptide activates a non-selective cation current in acutely isolated rat cardiac fibroblasts via natriuretic peptideC receptor-mediated signaling. Journal of Physiology, 580(1), 255-274. (Pubitemid 46470657)
66. Schnabolk, G. W., Gupta, B., Mulgaonkar, A., Kulkarni, M., & Sweet, D. H. (2010). Prganic anion transporter 6 (S/c22a20) specificity and sertoli cell-specific expression provide new insight on potential endogenous roles. Journal of Pharmaceutical Experimental Therapeutic, 334, 927-935.
67. Selen, A., Amidon, G. L., & Welling, P. G. (1982). Pharmacokinetics of probenecid following oral doses to human volunteers. Journal of Pharmaceutical Science, 71(11), 1238-1242. (Pubitemid 13230064)
68. Silva-Adaya, D., Pérez-De La Cruz, V., Villeda-Hernández, J., Carrillo-Mora, P., González-Herrera, I. G., García, E., et al. (2011). Protective effect of l-kynurenine and probenecid on 6-hydroxydopamine-induced striatal toxicity in rats: Implications of modulating kynurenate as a protective strategy. Neurotoxicology and Teratology, 33(2), 303-312.
69. Sirota, J. H., Yu, T. F., & Gutman, A. B. (1952). Effect of benemid (p-[di-n-propylsulfamyl]-benzoic acid) on urate clearance and other discrete renal functions in gouty subjects. Journal of Clinical Investigation, 31(7), 692-701.
70. Solomon, D., Avorn, J., Levin, R., & Brookhart, M. (2008). Uric acid lowering therapy: Prescribing patterns in a large cohort of older adults. Annals of Rheumatic Disease, 67, 609-613. (Pubitemid 351571922)
71. Smith, D. E., Gee, W. L., Brater, D. C., Lin, E. T., & Benet, L. Z. (1980). Preliminary evaluation of furosemide-probenecid interaction in humans. Journal of Pharmaceutical Science, 69(5), 571-575. (Pubitemid 10045879)
72. Stocker, S. L., Graham, G. G., McLachlan, A. J., Williams, K. M., & Day, R. O. (2011). Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout. The Journal of Rheumatology, 38, 5.
73. Talbott, J. H. (1951). Clinical and metabolic effects of benemid in gout. Bulletin on the Rheumatic Diseases, 2(1), 1-2.
74. Teng, G. G., Nair, R., & Saag, K. G. (2006). Pathophysiology, clinical presentation and treatment of gout. Drugs, 66(12), 1547-1563. (Pubitemid 44376344)
75. Tsien, R. Y., Rink, T. J., & Poenie, M. (1985). Measurement of cytosolic free Ca2+ in individual small cells using fluorescence microscopy with dual excitation wavelengths. Cell Calcium, 6(1-2), 145-157. (Pubitemid 15121399)
76. Utsynomiya, Y., Hara, Y., Ito, H., Okonogi, H., Miyazaki, Y., Hashimoto, Y., et al. (2010). Effects of probenecid on the pharmacokinetics of mizoribine and co-administration of the two drugs in patients with nephrotic syndrome. International Journal of Clinical Pharmacology Therapeutics, 48(11), 751-755.
77. van Praag, H. M., Korf, J., & Schut, D. (1973) Cerebral monoamines and depression. An investigation with the Probenecid technique. Archives of General Psychiatry, 28(6), 827-831.
78. van Praag, H. M., Flentge, F., Korf, L., Dols, L. C., & Schut, T. (1973). The influence of probenecid on the metabolism of serotonin, dopamine, and their precursors in man. Psychopharmacologia, 33, 141-151.
79. Vriens, J., Appendino, G., & Nilius, B. (2009). Pharmacology of vanilloid transient receptor potential cation channels. Molecular Pharmacolgy., 75, 1262-1279.
80. Wolf, D. L., Rodríguez, C. A., Mucci, M., Ingrosso, A., Duncan, B. A., & Nickens, D. J. (2003). Pharmacokinetics and renal effects of cidofovir with a reduced dose of probenecid in HIV-infected patients with cytomegalovirus retinitis. Journal of Clinical Pharmacology, 43(1), 43-51. (Pubitemid 36015442)
81. Wolfson, W. Q., Cohn, C., Levine, R., & Huddlestun, B. (1948). Transport and excretion of uric acid in man. III Physiological significance of the uricosuric effect of caronamide. American Federation for Clinical Research, 4(5), 774.
82. Wu, H., Liu, M., Wang, S., Feng, W., Yao, W., Zhao, H., et al. (2010). Pharmacokinetic properties and bioequivalence of two compound formulations of 1500 mg ampicillin (1167 mg)/ probenecid (333 mg): a randomized-sequence, single-dose, open-label, two-period crossover study in healthy Chinese male volunteers. Clinical Therapeutics, 32(3), 597-606.
83. Yü, T. F., & Gutman, A. B. (1951). Mobilization of gouty tophi by protracted use of uricosuric agents. American Journal of Medicine, 11(6), 765-769.